Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-11-15 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年11月法人說明會簡報 — 179520241112E003.pdf
Interim / Quarterly Report Classification · 98% confidence The document is titled 'LOTUS 3Q24 EARNINGS RESULTS Investor meeting Presentation' and contains detailed financial results for the third quarter of 2024, including revenue, gross profit, net income, EPS, margins, and segment performance. It also includes business highlights, acquisitions, R&D pipeline information, and outlook. The presence of comprehensive financial data and analysis for a quarter, along with business commentary, indicates this is a quarterly financial report. The document length is over 12,000 characters, and it is not merely an announcement or a brief summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-11-15 Chinese
113年11月法人說明會簡報 — 179520241112M003.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled '美時 2024 年第三季 營運成果報告' which translates to 'Medsil 2024 Q3 Operating Results Report'. It contains detailed financial data for the third quarter of 2024, including consolidated revenue, gross profit, net profit after tax, EPS, and segment revenue breakdowns. It also discusses operational highlights, acquisitions, product approvals, and market expansions. The presence of comprehensive financial statements and analysis for a quarter indicates this is a quarterly financial report. The document length is 9511 characters, which is substantial and contains actual financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-11-15 Chinese
113年11月法人說明會簡報 — 179520241112E002.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'LOTUS 3Q24 EARNINGS RESULTS Investor meeting Presentation' and contains detailed financial results for the third quarter of 2024, including revenue, gross profit, net income, EPS, margins, and segment performance. It also includes business highlights, acquisitions, R&D pipeline information, and outlook. The presence of comprehensive financial data and analysis for a quarter, along with business commentary, indicates this is a quarterly financial report. The document length is over 12,000 characters, and it is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-11-15 Chinese
113年11月法人說明會簡報 — 179520241112M002.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled "美時 2024 年第三季 營運成果報告" which translates to "Medsil 2024 Q3 Operating Results Report." It contains detailed financial data for the third quarter of 2024, including consolidated revenue, gross profit, net profit, EPS, and segment revenue breakdowns. It also discusses operational highlights, acquisitions, product approvals, and ESG ratings. The document is about a quarterly period and includes substantive financial statements and analysis, not just an announcement or summary. It is not a full annual report, audit report, or earnings release (which typically are shorter and more summary-focused). The detailed financial data and operational commentary align with the definition of an Interim / Quarterly Report (IR). The document length (9511 characters) and content confirm it is a comprehensive quarterly report rather than a brief announcement or presentation. Q3 2024
2024-11-15 Chinese
113年11月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing of scheduled investor presentations (法人說明會) with dates, times, locations, and links to presentation materials. It includes references to financial and operational status explanations for a specific quarter (113年第三季, which corresponds to Q3). The content is clearly about investor presentations rather than full financial reports or announcements. The document length is short (1657 characters), and it is a schedule or summary of investor presentations rather than the presentations themselves or a report. Therefore, the best classification is Investor Presentation (IP).
2024-11-15 Chinese
本公司受邀參加麥格理證券舉辦之 Macquarie Asia Conference 2024
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company (1795 美時) being invited to participate in the Macquarie Asia Conference 2024, including details of the date, time, and location of the event. It mentions a '法人說明會' which translates to 'investor presentation' or 'analyst meeting'. The document does not contain any financial statements or detailed financial data, nor does it include a transcript or report. It is essentially a notification of an upcoming investor presentation event. Therefore, the most appropriate classification is 'Investor Presentation (IP)'. The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear event details and context.
2024-11-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.